On April 5, 2023,
JP Morgan
maintained
coverage of Relay Therapeutics with
a Overweight recommendation.
Analyst Price Forecast Suggests 103.68% Upside
As of March 30, 2023,
the average one-year price target for Relay Therapeutics is $34.40.
The forecasts range from a low of $16.16 to a high of $48.30.
The average price target represents an increase of 103.68% from its latest reported closing price of $16.89.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Relay Therapeutics
is $16MM, an increase of 1,082.40%.
The projected annual non-GAAP EPS
is -$3.11.
What are Other Shareholders Doing?
MML SERIES INVESTMENT FUND – MML Small Cap Growth Equity Fund Initial Class
holds 23K shares
representing 0.02% ownership of the company.
In it’s prior filing, the firm reported owning 13K shares, representing
an increase
of 44.06%.
The firm
increased
its portfolio allocation in RLAY by 16.75% over the last quarter.
Brighthouse Funds Trust I – JPMorgan Small Cap Value Portfolio
holds 78K shares
representing 0.06% ownership of the company.
In it’s prior filing, the firm reported owning 80K shares, representing
a decrease
of 2.44%.
The firm
decreased
its portfolio allocation in RLAY by 37.20% over the last quarter.
FCFMX – Fidelity Series Total Market Index Fund
holds 102K shares
representing 0.08% ownership of the company.
In it’s prior filing, the firm reported owning 89K shares, representing
an increase
of 13.20%.
The firm
decreased
its portfolio allocation in RLAY by 10.27% over the last quarter.
FCTDX – Strategic Advisers Fidelity U.S. Total Stock Fund
holds 438K shares
representing 0.36% ownership of the company.
In it’s prior filing, the firm reported owning 329K shares, representing
an increase
of 24.86%.
The firm
increased
its portfolio allocation in RLAY by 1.14% over the last quarter.
EQ ADVISORS TRUST – EQ
holds 4K shares
representing 0.00% ownership of the company.
In it’s prior filing, the firm reported owning 3K shares, representing
an increase
of 11.93%.
The firm
decreased
its portfolio allocation in RLAY by 28.01% over the last quarter.
What is the Fund Sentiment?
There are 429 funds or institutions reporting positions in Relay Therapeutics.
This is an increase
of
3
owner(s) or 0.70% in the last quarter.
Average portfolio weight of all funds dedicated to RLAY is 0.19%,
a decrease
of 14.24%.
Total shares owned by institutions increased
in the last three months by 4.28% to 137,202K shares.
The put/call ratio of RLAY is 0.87, indicating a
bullish
outlook.
Relay Therapeutics Background Information
(This description is provided by the company.)
Relay Therapeutics, Inc. operates as a biotechnology company. The Company develops durgs for the treatment of cancer. Relay Therapeutics serves customers in the United States.
See all Relay Therapeutics regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
